Skip to content
Peptide Spencer
Partner

Blend

Tesamorelin / Ipamorelin / AOD-9604 / MOTS-c

Custom strengths on request

Compounded medications are not FDA-approved.

What is in the vial

Blend calculator

Blend vial

Pick the blend, then the one component your dose is written for. The others follow from the vial.

mL
Dose is written for
mcg

Result

0102030405060708090100

Draw to

-

Water in the vial
-
Dose anchored to
Tesamorelin

What each component delivers

Amount of each blend component in the drawn dose
ComponentDelivered
Tesamorelin10 mg in the vial-
Ipamorelin10 mg in the vial-
AOD-960410 mg in the vial-
MOTS-c10 mg in the vial-No established dose

Math on the numbers above. Not medical advice; confirm concentration against the dispensed vial label.

Each component at a glance

Tesamorelin

These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.

  1. Start

    1.4 mg subcutaneously once daily (EGRIFTA SV)

    Approved label
Frequency
Once daily
Route
Subcutaneous injection into the abdomen, rotating sites
Course
Pivotal trials: 26 weeks plus a 26-week extension
Label doses apply only to branded EGRIFTA vials; recalculate volume for compounded vials from the pharmacy's labeled mg/mL.
Calculate this dose

Full dosing guide

Ipamorelin

These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.

  1. Start

    0.03 mg/kg per dose, intravenous infusion (postoperative ileus trial)

    Human study
Frequency
twice daily
Route
intravenous infusion
Course
postoperative day 1 to 7 or hospital discharge
Both human studies used intravenous dosing only; no subcutaneous human dosing is established, so do not extrapolate these figures to subcutaneous use.
Calculate this dose

Full dosing guide

AOD-9604

These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.

  1. Start

    0.25 mg oral tablet daily (lowest fixed arm, phase IIb trial; no titration)

    Human study

  2. Ceiling

    1 mg oral tablet daily (top arm here; oral capsules to 30 mg daily also studied)

    Human study
Frequency
daily
Route
oral (tablets); no subcutaneous dosing trial found
Course
24 weeks after a 4-week placebo run-in
Trial doses were oral or intravenous only; never convert them to subcutaneous doses. Practice figures for subcutaneous use are convention, not evidence.
Calculate this dose

Full dosing guide

MOTS-c

These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.

No established human dose

No product containing MOTS-c is approved. FDA found no published human study of MOTS-c given by any route (May 2026 review). Evidence for exogenous dosing comes from mouse work (intraperitoneal). Human papers measure endogenous MOTS-c levels only. CB4211, an analog described by its developer, had a company-reported Phase 1a/1b (25 mg SC daily for 28 days in NAFLD). That study is not MOTS-c data. Clinic dosing rests on one provider blog. FDA found no in-vivo pharmacokinetic data, and an in-vitro study reports rapid hydrolysis in human blood. Whether exogenous dosing produces active concentrations is not established. The practice regimen is not derived from dose-response data, because FDA notes rodent studies did not assess dose-response in vivo.

No label or human study dosing exists for MOTS-c; FDA found no human dosing data for the exogenous peptide.
Open the calculator

Full dosing guide

Get a quote

Custom strengths on request. Prices are quoted per clinic.